- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- quaratusugene ozeplasmid, atezolizumab
- Biological
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 17
- States / cities
- Lone Tree, Colorado • St Louis, Missouri • Canton, Ohio + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer
- Interventions
- DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
- Drug
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy
- Biological · Drug
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- quaratusugene ozeplasmid, pembrolizumab, docetaxel, ramucirumab, Investigator's Treatment of Choice
- Biological · Drug
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Tampa, Florida • New Orleans, Louisiana • St Louis, Missouri + 3 more